Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2021-10-18 Governance Information
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
2021 Corporate Governance Statement and Appendix 4G 28 pages 923.1KB
Governance Information Classification · 95% confidence The document is titled '2021 Corporate Governance Statement' and discusses the company's corporate governance practices, board composition, director independence, nomination and appointment of directors, and board meetings. It references compliance with ASX Corporate Governance Council Principles and includes detailed governance policies and charters. There is no indication that this is an announcement of a report publication or a brief summary. The content is focused on governance practices and board structure rather than financial results or management discussion. Therefore, this document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-10-18 English
MAYNE PHARMA provides FDA update on generic NUVARING 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on the FDA status of Mayne Pharma's generic NuvaRing drug application. It discusses receipt of a complete response letter (CRL) from the FDA and the company's plans to address the FDA's questions. The document is short (2280 characters) and is clearly an announcement about regulatory progress rather than a detailed financial report or filing. There are no financial statements, no detailed management discussion, no voting results, no executive changes, and no legal proceedings detailed. It is not a report publication announcement since it does not mention a report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about FDA correspondence and drug approval status.
2021-10-06 English
Initial Director's Interest Notice 2 pages 136.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the initial director's relevant interests in securities and contracts, specifically for Dr Carolyn Myers, including appointment date and securities holdings (nil). This is a notification of a director's personal share transactions or interests, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director interests, not financial results or management changes. Therefore, the appropriate classification is Director's Dealing (DIRS).
2021-10-04 English
Mayne Pharma appoints new Director 2 pages 146.0KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 4 October 2021 about the appointment of a new director, Carolyn Myers, to the Board of Mayne Pharma Group Limited. It details her background, qualifications, and the context of her nomination by a significant shareholder. There is no financial data, no mention of a report or financial results, and the content focuses solely on management/board changes. The document length is 3625 characters, which is relatively short and consistent with a management announcement rather than a full report. Therefore, the document fits the category of Board/Management Information (MANG).
2021-10-03 English
Final Director's Interest Notice (x2) 4 pages 378.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the cessation of directors and their relevant interests in securities, including holdings and indirect interests. This type of document is a formal notification of personal share transactions or holdings by company directors. It is not a financial report, earnings release, or management discussion. It fits the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of director interests.
2021-10-03 English
Mayne Pharma adds generic ABSORICA to US portfolio 2 pages 152.4KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 29 September 2021, describing Mayne Pharma's new distribution agreement for generic isotretinoin capsules in the US dermatology market. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or strategic presentations. The content is a corporate announcement about a commercial partnership and product launch. The document length is 4494 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a regulatory filing. Therefore, the document best fits the category of a Capital/Financing Update (CAP) as it relates to a new distribution agreement and product launch impacting the company's commercial activities and potentially its capital structure or revenue streams.
2021-09-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.